Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
Résumé
Key Points In adult patients with core binding factor AML, intensified induction is not associated with a better outcome in the context of intensive postremission therapy. Minimal residual disease, rather than KIT or FLT3 gene mutations, should be used to identify core binding factor AML patients at higher risk of relapse.